Pinealon (20mg Vial) Dosage Protocol

Quickstart Highlights

Pinealon (also known as EDR; sequence Glu‑Asp‑Arg) is an ultrashort tripeptide investigated for neuroprotective and epigenetic regulatory effects, with most peer‑reviewed data from in vitro and animal studies and limited human observations^[1]^[2]^[3]^[4]^[5]. Published literature frequently describes oral administration in clinical contexts; subcutaneous (SC) human dosing is not established and the SC framework below is educational for research settings only^[4]^[5].

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.

Research-use daily range (educational): 200–500 mcg once daily with gradual titration (SC route not defined in clinical trials; see Evidence note above).

Insulin‑syringe math: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: store at −20 °C (−4 °F) protected from light; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); minimize freeze–thaw cycles^[12]^[13].

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing (research use only).

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Route & frequency: Once‑daily subcutaneous (research framework). Evidence note: Peer‑reviewed reports most often describe oral administration in human contexts; subcutaneous human dosing for Pinealon is not established in clinical trials^[4]^[5].

Week	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	200 mcg (0.20 mg)	3 units (0.03 mL)
Weeks 3–4	300 mcg (0.30 mg)	4.5 units (0.045 mL)
Weeks 5–6	400 mcg (0.40 mg)	6 units (0.06 mL)
Weeks 7–12	500 mcg (0.50 mg)	7.5 units (0.075 mL)

Measuring note: For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light^[12]^[13].

Evidence framing: Most mechanistic and efficacy data for Pinealon/EDR derive from cell and animal models; limited clinical observations exist and often use oral dosing regimens^[1]^[2]^[3]^[4]^[5].

Supplies Needed

Planning for 8–16 weeks of once‑daily administration (research framework).

Peptide Vials (Pinealon, 20 mg each):

8 weeks ≈ 1 vial (≈19.6 mg total)
12 weeks ≈ 2 vials (≈33.6 mg total)
16 weeks ≈ 3 vials (≈47.6 mg total)

Insulin Syringes (U‑100):

Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial.

8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
16 weeks (3 vials): 9 mL → 1 × 10 mL bottle

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)
8 weeks: 112 swabs → recommend 2 × 100‑count boxes
12 weeks: 168 swabs → recommend 2 × 100‑count boxes
16 weeks: 224 swabs → recommend 3 × 100‑count boxes

View Supplier

Protocol Overview

Cautious, research‑only framework reflecting current evidence limitations.

Goal: Study neuroprotective and stress‑response pathways influenced by EDR/Pinealon^[1]^[3]^[5].

Schedule: Once‑daily subcutaneous injections for 8–12 weeks (optional extension to 16 weeks); note oral dosing dominates human literature^[4]^[5].

Dose Range: 200–500 mcg daily with gradual titration (educational; not derived from SC clinical trials).

Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for clear syringe conversions.

Storage: Lyophilized at −20 °C (−4 °F); reconstituted at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw^[12]^[13].